Repligen Corp. Stock
Price
Target price
€127.75
€127.75
0.820%
1.0
0.820%
€148.47
25.06.26 / Tradegate
WKN: 870980 / Symbol: RGEN / Name: Repligen Corp / Stock / Pharmaceuticals / Mid Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Repligen Corp. Stock
The Repligen Corp. stock is trending slightly upwards today, with an increase of €1.00 (0.820%) compared to yesterday's price.
With 19 Buy predictions and not the single Sell prediction the community is currently very high on Repligen Corp..
With a target price of 148 € there is a slightly positive potential of 15.85% for Repligen Corp. compared to the current price of 127.75 €.
So far the community has only identified positive things for Repligen Corp. stock. The most positive votes were given for criterium "Worthwhile Investment for the next years".
Pros and Cons of Repligen Corp. in the next few years
Pros
?
B****
?
S********** s********
?
C******** o* t** e**********
Cons
?
M***** P*******
?
W********* I********* f** t** n*** y****
?
G***** c******* t* c**********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Repligen Corp. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Repligen Corp. | 0.820% | 10.894% | 28.032% | 20.292% | -9.301% | -7.023% | -20.405% |
| Opko Health Inc. | -2.270% | 6.612% | 25.243% | 18.436% | 18.327% | -7.936% | -58.293% |
| Guangzhou Baiyunshan Pharmaceutical Holdings Co. Ltd. | -1.250% | -1.863% | -7.059% | -15.508% | -19.388% | -36.800% | -32.479% |
| China Traditional Chinese Medicine Co Ltd | 0.000% | 0.000% | 0.000% | -7.563% | 0.917% | -46.078% | -58.491% |
Comments
Repligen (RGEN) had its price target lowered by HSBC Holdings plc from $170.00 to $150.00. They now have a "buy" rating on the stock.
Show more
Ratings data for RGEN provided by MarketBeat
Repligen (RGEN) had its "outperform" rating reaffirmed by Wolfe Research. They now have a $145.00 price target on the stock.
Show more
Ratings data for RGEN provided by MarketBeat
Repligen (RGEN) had its price target lowered by JPMorgan Chase & Co. from $180.00 to $165.00. They now have an "overweight" rating on the stock.
Show more
Ratings data for RGEN provided by MarketBeat
